

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



2023 INTERIM RESULTS ANNOUNCEMENT

The board of directors (the “**Board**”) of AMCO United Holding Limited (the “**Company**”) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries for the six months ended 30 June 2023. This announcement, containing the full text of the 2023 Interim Report of the Company, complies with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in relation to information to accompany preliminary announcement of interim results.

For and on behalf of the Board
AMCO United Holding Limited
ZHANG Hengxin
Chairman and Managing Director

Hong Kong, 28 August 2023

As at the date of this announcement, Mr. Zhang Hengxin and Mr. Jia Minghui are the Executive Directors; and Ms. Ye Mengmei, Mr. Au Yeung Ming Yin Gordon and Mr. Guo Zhenhui are the Independent Non executive Directors.

* *For identification purposes only*

Contents

目錄

Management Discussion and Analysis	管理層討論及分析	2
Corporate Governance and Other Information	企業管治及其他資料	13
Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	簡明綜合中期損益及其他全面收益表	21
Interim Condensed Consolidated Statement of Financial Position	簡明綜合中期財務狀況表	22
Interim Condensed Consolidated Statement of Changes in Equity	簡明綜合中期權益變動表	23
Interim Condensed Consolidated Statement of Cash Flows	簡明綜合中期現金流量表	24
Notes to the Interim Condensed Consolidated Financial Statements	簡明綜合中期財務報表附註	25

Management Discussion and Analysis

管理層討論及分析

RESULTS, BUSINESS REVIEW AND PROSPECTS

Results

For the six months ended 30 June 2023, AMCO United Holding Limited (the “Company”) and its subsidiaries (collectively referred to as the “Group”) are principally engaged in (i) manufacture and sale of medical devices products (“Medical Products Business”); (ii) manufacture and sale of plastic moulding products (“Plastic Products Business”); (iii) provision of construction services in building construction, building maintenance and improvement works, project management, renovation and decoration works (“Building Contract Works Business”); (iv) provision of money lending (“Money Lending Business”); and (v) investment in securities (“Securities Investment”).

During the period under review, revenue of the Group amounted to HK\$23.3 million, representing a decrease of HK\$1.7 million or 6.8% from HK\$25.0 million for the corresponding period last year. Such decrease was mainly attributable to the decrease in revenue from the Medical Products Business, Plastic Moulding Business and Building Contract Works Business.

Gross profit of the Group was HK\$4.9 million, representing a decrease of HK\$2.2 million or 31.0% as compared to HK\$7.1 million for the corresponding period last year. Gross profit margin slightly decreased by 7.2 percentage points to 21.1% (30 June 2022: 28.3%).

Other losses, net of other income and other gains, during the period under review recorded loss of HK\$20.3 million as compared to loss of HK\$10.6 million in the corresponding period of 2022. The amount included realised and unrealised fair value gain/(loss) of held-for-trading investments arising from Securities Investment and the change of fair value on financial liabilities at fair value through profit or loss in the current period.

業績、業務回顧及前景

業績

截至二零二三年六月三十日止六個月，雋泰控股有限公司（「本公司」）及其附屬公司（統稱為「本集團」）之主要業務為(i)製造及銷售醫療設備產品（「醫療產品業務」）；(ii)製造及銷售塑膠模具產品（「塑膠產品業務」）；(iii)提供樓宇建造、樓宇維修及改善工程、項目管理、裝修及裝飾工程方面之建造服務（「樓宇承包工程業務」）；(iv)提供放貸（「放貸業務」）；及(v)證券投資（「證券投資」）。

於回顧期間，本集團之收入為23,300,000港元，較去年同期之25,000,000港元減少1,700,000港元或6.8%。該減少乃主要由於來自醫療產品業務、塑膠模具業務及樓宇承包工程業務之收入減少所致。

本集團毛利為4,900,000港元，較去年同期之7,100,000港元減少2,200,000港元或31.0%。毛利率略微減少7.2個百分點至21.1%（二零二二年六月三十日：28.3%）。

其他虧損（扣除其他收入及其他收益）於回顧期間錄得虧損20,300,000港元，而二零二二年同期為虧損10,600,000港元。該金額包括本期間證券投資產生之持作買賣投資已變現及未變現公允價值收益／（虧損）及透過損益按公允價值列賬之財務負債之公允價值變動。

The distribution costs decreased by HK\$0.5 million to HK\$2.7 million during the period under review (30 June 2022: HK\$3.2 million), alongside with the decrease in revenue of Medical Products Business and Plastic Products Business. The administrative expenses decreased by HK\$11.6 million to HK\$10.1 million (30 June 2022: HK\$21.7 million), representing a decrease of 53.5% over the corresponding period last year, primarily as a result of the combined effect of (i) the decrease in general administrative costs under stringent cost control during the current period; and (ii) the recognition of share-based payment expense of HK\$9.2 million during the period ended 30 June 2022.

Finance costs amounted to HK\$1.4 million (30 June 2022: HK\$1.8 million) for the period under review, which represented interest on bond payables and lease liabilities.

As a result, the overall loss attributable to owners of the Company was HK\$29.7 million, which decreased by HK\$0.5 million as compared to HK\$30.2 million loss for the corresponding period of 2022. Excluding the other income and other gains or losses and the share-based payment expenses, the loss for the six months ended 30 June 2023 was HK\$9.4 million, which decreased by HK1.0 million as compared to HK\$10.4 million loss for the corresponding period of 2022.

Business Review

Medical Products Business

For the six months ended 30 June 2023, the revenue from the Medical Products Business decreased by HK\$0.6 million or 3.5% to HK\$16.4 million, as compared to revenue of HK\$17.0 million recorded in the same period last year, which accounted for 70.4% of the Group's total revenue for the period under review. In the first half of 2023, the sales demand of Medical Products Business decrease due to the keen competition in the industry.

於回顧期間，分銷成本減少500,000港元至2,700,000港元（二零二二年六月三十日：3,200,000港元），連同醫療產品業務及塑膠產品業務之收入減少。行政開支減少11,600,000港元至10,100,000港元（二零二二年六月三十日：21,700,000港元），較去年同期減少53.5%，乃主要由於(i)於本期間嚴格控制成本項下一般行政成本減少；及(ii)於截至二零二二年六月三十日止期間確認以股份為基礎之付款開支9,200,000港元的合併影響所致。

於回顧期間，財務費用為1,400,000港元（二零二二年六月三十日：1,800,000港元），該費用指應付債券及租賃負債的利息。

因此，本公司擁有人應佔整體虧損為29,700,000港元，較二零二二年同期之虧損30,200,000港元減少500,000港元。扣除其他收入及其他收益或虧損以及以股份為基礎之付款開支，截至二零二三年六月三十日止六個月的虧損為9,400,000港元，較二零二二年同期之虧損10,400,000港元減少1,000,000港元。

業務回顧

醫療產品業務

截至二零二三年六月三十日止六個月，醫療產品業務之收入減少600,000港元或3.5%至16,400,000港元，而去年同期錄得收入17,000,000港元，佔本集團於回顧期間總收入之70.4%。於二零二三年上半年，醫療產品業務的銷售需求因行業競爭激烈而有所減少。

Management Discussion and Analysis

管理層討論及分析

Segment profit of the Medical Products Business amounted to HK\$1.4 million for the six months ended 30 June 2023, as compared to segment profit of HK\$1.0 million in the corresponding period last year. To cope with the challenge of fluctuating sales order, the Group is persisting to deploy business strategies of streamlining and outsourcing of business processes, implementing strict cost control and ensuring effective utilisation of resources with an aim to maintain its long-term sustainable competitive advantages in the business segment. In the meantime, the Group is actively exploring and identifying potential business opportunities to expand its customer base and also the products and services portfolio of the business segment in order to generate and broaden the income streams of the Medical Products Business.

Plastic Products Business

The revenue from the Plastic Products Business decreased by HK\$0.6 million or 50.0% to HK\$0.6 million for the six months ended 30 June 2023, as compared to HK\$1.2 million in the corresponding period last year, which accounted for 2.7% of the Group's total revenue for the period under review. The decrease mainly attributable to the decrease in sales order due to keen competition in the industry.

Although with persistent efforts in the improvement in profit margins of sales orders and cost control in the reduction of distribution costs and administrative expenses, the Group decreased the segment profit of HK\$0.3 million for the corresponding period of 2022 to a profit of HK\$0.2 million for the period under review due to the decrease in sales order.

截至二零二三年六月三十日止六個月，醫療產品業務分部溢利為1,400,000港元，而去年同期之分部溢利為1,000,000港元。為應對銷售訂單波動的挑戰，本集團堅持施行精簡及外判業務流程、落實嚴緊成本控制及確保資源有效利用之業務策略，以維持其於該業務分部之長期可持續競爭優勢。同時，本集團正積極開拓及識別潛在業務商機以擴展其業務分部之客戶群以及產品及服務組合，以產生及擴寬醫療產品業務之收入流。

塑膠產品業務

塑膠產品業務之收入較去年同期之1,200,000港元，減少600,000港元或50.0%至截至二零二三年六月三十日止六個月之600,000港元，佔本集團於回顧期間總收入之2.7%。該減少乃主要由於行業競爭激烈導致銷售訂單減少所致。

儘管堅定不移地改善銷售訂單之利潤率及通過降低分銷成本及行政開支實行成本控制，但由於銷售訂單減少，本集團由二零二二年同期之分部溢利300,000港元減少至回顧期間之溢利200,000港元。

Building Contract Works Business

For the six months ended 30 June 2023, revenue from the Building Contract Works Business generated by ACE Engineering Limited (“ACE Engineering”), a wholly-owned subsidiary of the Company, amounted to HK\$0.3 million, representing a decrease of HK\$1.0 million or 76.9% as compared to HK\$1.3 million for the corresponding period of 2022, which contributed 1.1% of the Group’s total revenue for the period under review. The decrease in revenue was primarily due to decrease in awards of projects in both public and private sectors, under the stringent and competitive market environment of the building construction and maintenance industry caused by slower growth of the industry and the Hong Kong economy during the period. This business recorded a gross profit of HK\$0.1 million (30 June 2022: HK\$0.2 million) and gross profit margin of 17.9% (30 June 2022: 14.7%). The increase in gross profit margin was primarily attributable to decrease in subcontracting costs as a result of continued efforts in controlling and managing the costs. Segment loss of this business decreased by HK\$0.6 million or 75.0% to HK\$0.2 million for the six months ended 30 June 2023, as compared to that of HK\$0.8 million for the corresponding period of 2022, primarily due to the decrease in administrative expenses caused by decreased staff costs.

樓宇承包工程業務

截至二零二三年六月三十日止六個月，安迪工程有限公司（「安迪工程」，本公司之全資附屬公司）所產生來自樓宇承包工程業務之收入為300,000港元，較二零二二年同期之1,300,000港元減少1,000,000港元或76.9%，佔本集團於回顧期間總收入之1.1%。收入減少乃主要由於期內行業及香港經濟增長放緩導致樓宇建造及維修行業的市場環境嚴峻及競爭激烈，獲授的公共及私營部門的項目減少。該業務錄得毛利100,000港元（二零二二年六月三十日：200,000港元）及毛利率17.9%（二零二二年六月三十日：14.7%）。毛利率增加乃主要由於持續努力管控成本令分包成本減少。該業務之分部虧損較二零二二年同期之800,000港元減少600,000港元或75.0%至截至二零二三年六月三十日止六個月之200,000港元，乃主要由於員工成本減少導致行政開支減少所致。

Management Discussion and Analysis

管理層討論及分析

Despite reduction in segment loss of the business during the period under review, segment revenue and results of this business indicated that market environment of the building construction and maintenance industry is still stringent. The Group will continue to deploy efforts in tendering for projects in both public and private sectors, particularly projects which yield higher margins in price, and make concerted efforts in controlling and managing contract and operating costs, in order to facilitate improvement in results of this business.

Money Lending Business

For the six months ended 30 June 2023, the Group recorded loan interest income of HK\$6.0 million from its Money Lending Business, representing an increase of HK\$0.5 million or 9.1% as compared to HK\$5.5 million for the corresponding period last year, which accounted for 25.8% of the Group's total revenue for the period under review. Segment loss of the Money Lending Business amounted to HK\$0.8 million (30 June 2022: loss of HK\$1.3 million). The outstanding principal and interest amount of loan receivables as at 30 June 2023 was HK\$94.3 million (31 December 2022: HK\$90.1 million). The Group will continue to develop this business by employing prudent credit control procedures and strategies to hold a balance between the business growth and the risk management.

儘管該業務於回顧期間之分部虧損減少，但此業務之分部收入及業績表明樓宇建造及維修行業之市場環境仍然嚴峻。本集團將繼續努力投標公共及私營部門之項目，尤其是價格利潤率較高的項目，並協力管控合約和營運成本，以促進該業務業績改善。

放貸業務

截至二零二三年六月三十日止六個月，本集團錄得放貸業務貸款利息收入6,000,000港元，較去年同期之5,500,000港元增加500,000港元或9.1%，佔本集團回顧期間總收入之25.8%。放貸業務之分部虧損為800,000港元（二零二二年六月三十日：虧損1,300,000港元）。於二零二三年六月三十日，應收貸款之未償還本金額及利息為94,300,000港元（二零二二年十二月三十一日：90,100,000港元）。本集團將透過採用審慎信貸控制程序及維持業務增長與風險管理相平衡策略，繼續發展該業務。

Securities Investment

During the period under review, the Group recorded net unrealised and realised loss of HK\$11.0 million (30 June 2022: loss of HK\$10.7 million) arising on change in fair value of held-for-trading investments of listed equity securities in Hong Kong for the six months ended 30 June 2023. No dividend income was received from the held-for-trading investments during the period under review (30 June 2022: nil). Segment loss of the Securities Investment amounted to HK\$11.0 million (30 June 2022: loss of HK\$10.7 million).

As at 30 June 2023, the Group held 19 listed equity securities in Hong Kong with the fair value of HK\$23.9 million. In light of the recent volatile financial market in Hong Kong, the Group intends to diversify its investment portfolio in order to reduce the relevant concentration and investment risks and will closely monitor the performance of this business. The Group will keep adopting a prudent investment attitude and develop its investment strategy with the aim to improve the capital usage efficiency and generate additional investment returns on the idle funds of the Group.

Details of the Group's held-for-trading investments as at 30 June 2023 are as follows:

證券投資

於回顧期間，本集團因截至二零二三年六月三十日止六個月香港上市股本證券持作買賣投資之公允價值變動而錄得未變現及已變現虧損淨額11,000,000港元（二零二二年六月三十日：虧損10,700,000港元）。於回顧期間，並無自持作買賣投資收到任何股息收入（二零二二年六月三十日：無）。證券投資分部虧損為11,000,000港元（二零二二年六月三十日：虧損10,700,000港元）。

於二零二三年六月三十日，本集團持有之19隻香港上市股本證券之公允價值為23,900,000港元。鑒於近期香港金融市場動盪，本集團擬多元化其投資組合以減低有關集中及投資風險，並將密切監察該業務之表現。本集團將繼續採取審慎投資態度及制定其投資策略，旨在提高資本利用率及利用本集團閒置資金帶來額外投資回報。

於二零二三年六月三十日，本集團之持作買賣投資之詳情如下：

Company Name/Stock Code	公司名稱／股份代號	% of shareholding as at 30 June 2023	Realised and unrealised (loss)/gain for the period ended 30 June 2023	Fair value as at 30 June 2023	% of total assets of the Group as at 30 June 2023
		佔於二零二三年六月三十日之股權百分比	截至二零二三年六月三十日止期間之已變現及未變現(虧損)/收益	於二零二三年六月三十日之公允價值	佔本集團於二零二三年六月三十日之資產總值百分比
			HK\$'000 千港元	HK\$'000 千港元	
Securities listed in Hong Kong	香港上市證券				
WLS Holdings Limited	滙隆控股有限公司				
("WLS") (8021) (Note (a))	(「滙隆」) (8021) (附註(a))	1.4%	(2,344)	11,130	6.9%
Others (Note (b))	其他 (附註(b))		(8,670)	12,763	7.9%
			(11,014)	23,893	14.8%

Management Discussion and Analysis

管理層討論及分析

Notes:

(a) WLS is principally engaged in the provision of scaffolding, fitting out and other auxiliary services for construction and buildings work, money lending business, securities investment business and assets management business. As disclosed in the annual report of WLS for the year ended 30 April 2023, it recorded audited net loss attributable to its owners of HK\$112.4 million for the year ended 30 April 2023. With regards to the future prospects of WLS, the Directors noted that WLS is prudently optimistic about its prospects, at the same time cautious of the economic uncertainties brought by the outbreak of COVID-19. WLS is reviewing its existing assets structure and business strategies and may make adjustment to their existing assets structure, with the aim to consolidate their resources, so as to be flexibly prepared for uncertainties in the future. Meanwhile, in order to enhance their competitiveness, WLS will look for opportunities to revitalise the scaffolding business to keep up with the recent development and trend in the industry, in particular the declining use of bamboo scaffolds. At the same time, WLS will continue focusing on those business segments that generate higher profit margins and show ample growth potential such as money lending operations. WLS will strictly adhere to its cost control policy, and swiftly adjust business strategies of its scaffolding business in response to ever-changing market dynamics in order to generate better financial returns for their shareholders.

The Group's investment strategy is to deliver a diversified and flexible investment portfolio that will maximize sustained long-term returns and strive to achieve high growth, while the traditional business of the Group will continue its stable growth.

The Group's total investment in WLS was approximately HK\$45.5 million. As at 30 June 2023, the Group owned 195,270,000 shares of WLS, representing 1.4% equity interests in WLS with a carrying amount of the Group's interest in WLS of approximately HK\$11.1 million, representing approximately 6.9% of the total assets of the Company as at 30 June 2023. Up to 30 June 2023, no dividends was received from WLS. The fair value of WLS is based on quoted market prices.

(b) None of these investments represented more than 5% of the total assets of the Group as at 30 June 2023.

附註：

(a) 滙隆主要從事提供棚架搭建、精裝修及其他配套建造及樓宇工程服務、放貸業務、證券投資業務以及資產管理業務。誠如滙隆截至二零二三年四月三十日止年度之年度報告所披露，截至二零二三年四月三十日止年度，滙隆錄得其擁有人應佔經審核虧損淨額112,400,000港元。就滙隆之未來前景而言，董事注意到滙隆對其前景持審慎樂觀態度，同時對新型冠狀病毒爆發所帶來的經濟不確定性持審慎態度。滙隆正審閱其現有資產架構及業務策略並可能對現有資產架構作出調整，旨在整合資源，以靈活應對未來的不確定性。同時，為提高競爭力，滙隆正尋求盤活棚架搭建業務的機會，以緊貼當前的行業發展及趨勢，尤其是竹棚架的使用減少。同時，滙隆亦將繼續專注於利潤率較高及發展潛力巨大的業務分部，如放貸業務。滙隆將嚴格遵守成本控制政策，迅速調整棚架搭建業務的業務策略，以應對變幻莫測的市場動態，從而為股東創造更多財務回報。

本集團的投資戰略為構建一個多元化及靈活的投資組合，最大化可持續長期回報並努力實現高增長，同時本集團傳統業務將繼續穩定增長。

本集團於滙隆的投資總額約為45,500,000港元。於二零二三年六月三十日，本集團擁有195,270,000股滙隆股份，佔滙隆1.4%股權，本集團於滙隆的權益的賬面金額約為11,100,000港元，佔本公司於二零二三年六月三十日資產總值約6.9%。直至二零二三年六月三十日，並無自滙隆收取股息。滙隆的公允價值根據市場報價計算。

(b) 於二零二三年六月三十日，該等投資概無佔本集團資產總值之5%以上。

Looking ahead, the Directors believe that the future performance of the above investments held by the Group will be volatile and substantially affected by overall economic environment, equity market conditions, investor sentiment and the business performance and development of the investee companies. Accordingly, the Group will continue to maintain a diversified portfolio of investment of various industries to minimise the possible financial risks. Also, the Directors will cautiously assess the performance progress of the investment portfolio from time to time.

Prospects

Facing elevated challenges as we step into the year 2023 with the recovery of the economy as well as the highly volatile financial market in Hong Kong and globally, the Group will persist to build on its diversified business portfolio and focus its steps to formulate, evaluate and modify business strategies of our existing businesses in order to facilitate and motivate their business development and stabilise any downturn impact. To cope with the business development of the business segments, the Group will strive to deploy effective and sufficient capital and resources allocation in respect of the different business segments, and actively reallocate its assets, funding and labour force in response to the changing market and industry conditions and business results. The Group will conduct constant and dynamic performance appraisals and assessment to evaluate the ongoing business development. The Group will also concentrate on maintaining liquidity by effectively managing working capital and controlling costs, and leveraging operation efficiency by adhering to its lean organisation structure, in light of any difficulties which may be encountered under the uncertainties in the economy and financial market.

Alongside with the continuing evolution and modification of business strategies to develop our existing businesses, the Group will continue to seek optimisation of its business portfolio by adjusting it to adapt to the changing business climate, trend and environment, and at the same time proactively exploring and exploiting every potentially profitable business and investment opportunity as well as new growth potentials, with the ultimate goal of developing its business to generate and maximise shareholders' value and return and maintain sustainable growth and prosperity.

展望未來，董事認為本集團所持之上述投資未來表現將會波動並受整體經濟環境、股市狀況、投資者情緒以及被投資公司之業務表現及發展的重大影響。因此，本集團將繼續維持一個涉及多個行業投資之多元化組合，以將潛在金融風險減至最低。此外，董事將不時審慎評估投資組合之表現進度。

前景

進入二零二三年以來，面對由香港乃至全球經濟復甦以及金融市場劇烈波動帶來的多重挑戰，本集團將堅持基於多元化的業務組合並著重採取措施制定、評估及修訂現有業務的業務策略，以促進及激勵其業務發展並穩住任何下滑影響。就業務分部的業務發展而言，本集團將致力於就不同業務分部進行有效及充分的資金及資源分配，並因應市場變化、行業狀況及業務表現積極重新配置其資產、資金及人力。本集團將進行持續及動態的表現評價及評估以衡量持續業務發展。鑒於經濟及金融市場動盪可能帶來的任何困難，本集團亦將專注於透過有效管理營運資金及控制成本以維持流動資金，同時維持其精益組織結構以提高營運效率。

除了不斷更新及修改業務策略以發展現有業務，本集團將繼續努力應對不斷變化的營商氣候、趨勢及環境優化其業務組合，同時積極探索及利用每個潛在盈利業務及投資機會以及新增長潛力，從而實現發展其業務以產生並最大化股東價值與回報及保持可持續增長及繁榮的最終目標。

FINANCIAL REVIEW

Capital structure

As of 30 June 2023, the Group's consolidated net asset was approximately HK\$36.5 million, representing an increase of approximately HK\$17.9 million as compared to that of HK\$18.6 million as at 31 December 2022.

As at 30 June 2023, the Company has 967,551,792 (31 December 2022: 483,775,896) ordinary shares of HK\$0.05 each in issue.

During the six months ended 30 June 2023, the Group carried out the rights issue on basis of one rights shares for every one share. The Group completed the rights issue on 1 February 2023.

Rights Issue and Use of Proceeds

On 1 February 2023, an aggregate of 483,775,896 rights shares has been issued pursuant to the rights issue prospectus of the Company dated 30 December 2022 and the allotment results announcement of the Company dated 1 February 2023. The estimated net proceeds from the rights issue will accordingly be approximately HK\$46.5 million. The Company intended to apply the net proceeds from the rights issue for (i) approximately 71.4% or HK\$33.2 million of the net proceeds from the Rights Issue for the repayment of the bond payables; and (ii) approximately 28.6% or HK\$13.3 million of the net proceeds from the Rights Issue for general working capitals of the Group of which (1) approximately HK\$1.8 million for the payment of bond interest for the next 12 months; (2) approximately HK\$5.3 million for the payment of salaries of the Group's employees for the next 12 months; (3) approximately HK\$6.2 million for the working capital for the existing business for the next 12 months.

財務回顧

資本架構

截至二零二三年六月三十日，本集團之綜合資產淨值為約36,500,000港元，較於二零二二年十二月三十一日之18,600,000港元增加約17,900,000港元。

於二零二三年六月三十日，本公司有967,551,792股（二零二二年十二月三十一日：483,775,896股）每股面值0.05港元之已發行普通股。

截至二零二三年六月三十日止六個月，本集團按每持有一股股份獲發一股供股股份的基準進行供股。本集團已於二零二三年二月一日完成供股。

供股及所得款項用途

於二零二三年二月一日，已根據本公司日期為二零二二年十二月三十日的供股章程及本公司日期為二零二三年二月一日的配發結果公告發行合共483,775,896股供股股份。供股的估計所得款項淨額將相應約為46,500,000港元。本公司擬動用供股之所得款項淨額(i)約71.4%或33,200,000港元以償還應付債券；及(ii)約28.6%或13,300,000港元作為本集團的一般營運資金，其中(1)約1,800,000港元用於支付未來十二個月的債券利息；(2)約5,300,000港元用於支付本集團僱員未來十二個月的薪資；(3)約6,200,000港元用作現有業務未來十二個月的營運資金。

Up to 30 June 2023, (i) approximately HK\$33.2 million of the net proceeds has been utilised for repayment of the bond payables; (ii) approximately HK\$1.6 million of the net proceeds for the payment of salaries of the Group's employees; (iii) approximately HK\$0.2 million of the net proceeds for the payment of bond interest; and (iv) approximately HK\$5.2 million for the working capital for the existing business. The expected timeline for utilization of the unused net proceeds will be on or before 31 December 2023.

Details of the rights issue were disclosed in the Company's prospectus dated 30 December 2022 and the Company's announcement dated 1 February 2023.

Except for the changes mentioned elsewhere in the interim report, there has been no change in the capital structure of the Company since then.

Debt structure

The Group's total borrowings from financial institutions were zero as at 30 June 2023 and 31 December 2022. The Group's total cash and bank balances amounted to approximately HK\$10.8 million as at 30 June 2023, which increased HK\$7.1 million as compared to that of HK\$3.7 million as at 31 December 2022.

As at 30 June 2023, the Company had bond payables of HK\$30.0 million (31 December 2022: HK\$30.9 million) which represented unlisted bonds issued to independent third parties with an aggregate principal amount of HK\$6 million, which will mature in July 2025, HK\$4 million, which will mature in July 2026 and HK\$20 million, which will mature in March 2030.

The Group's gearing ratio was 53.3% as at 30 June 2023 (31 December 2022: 277.1%). The ratio was determined by net debt, which was defined as total interest-bearing liabilities comprising bond payables and lease liabilities less cash and cash equivalents, over shareholders' equity.

截至二零二三年六月三十日，(i)所得款項淨額的約33,200,000港元已用於償還應付債券；(ii)所得款項淨額的約1,600,000港元已用於支付本集團僱員的薪資；(iii)所得款項淨額的約200,000港元已用於支付債券利息；及(iv)約5,200,000港元已用於現有業務的營運資金。預期尚未動用所得款項淨額之使用時間將為二零二三年十二月三十一日或之前。

供股的詳情於本公司日期為二零二二年十二月三十日的供股章程以及本公司日期為二零二三年二月一日的公告中披露。

除中期報告其他部分所提述的變動外，本公司的資本架構自此概無發生任何變動。

債務架構

於二零二三年六月三十日及二零二二年十二月三十一日，本集團來自金融機構之總借貸為零。於二零二三年六月三十日，本集團之現金及銀行結餘總額為約10,800,000港元，較於二零二二年十二月三十一日之3,700,000港元增加7,100,000港元。

於二零二三年六月三十日，本公司的應付債券為30,000,000港元（二零二二年十二月三十一日：30,900,000港元），即向獨立第三方發行的本金總額為6,000,000港元（將於二零二五年七月到期）、4,000,000港元（將於二零二六年七月到期）及20,000,000港元（將於二零三零年三月到期）之非上市債券。

本集團於二零二三年六月三十日之資產負債比率為53.3%（二零二二年十二月三十一日：277.1%）。該比率乃由淨債務除以股東權益釐定，淨債務定義為計息負債（包括應付債券及租賃負債）總額減現金及現金等價物。

Management Discussion and Analysis 管理層討論及分析

Working capital and liquidity

As at 30 June 2023, the Group's current ratio were 1.6 (31 December 2022: 1.7).

Contingent liabilities and charges

The Group had not pledged any assets to secure bank facilities and other borrowings as at 30 June 2023 and 31 December 2022. The Group had no material contingent liability as at 30 June 2023 and 31 December 2022.

Foreign currency exposure

The Group's monetary assets, liabilities and transactions are mainly denominated in United States dollars, Renminbi and Hong Kong dollars. Since Hong Kong dollars are pegged to United States dollars and the exchange rate of Renminbi to Hong Kong dollars was relatively stable during the period, the Group's exposure to the potential foreign currency risk was relatively limited.

EMPLOYEES AND REMUNERATION POLICIES

As at 30 June 2023, the Group had 30 (31 December 2022: 30) employees. The Group's employees are remunerated largely based on their performance and experience, alongside with the current industry practices. Remuneration packages of employees include salaries, insurance, mandatory provident fund and share option scheme. Other employee benefits include medical cover, housing allowance and discretionary bonuses.

INTERIM DIVIDEND

The board of directors (the "Board") of the Company does not recommend the payment of an interim dividend for the six months ended 30 June 2023 (30 June 2022: nil).

營運資金及流動資金

於二零二三年六月三十日，本集團之流動比率為1.6(二零二二年十二月三十一日：1.7)。

或然負債及抵押

於二零二三年六月三十日及二零二二年十二月三十一日，本集團並無抵押任何資產，作為銀行信貸及其他借貸之擔保。於二零二三年六月三十日及二零二二年十二月三十一日，本集團並無重大或然負債。

外幣風險

本集團之貨幣資產、負債及交易主要以美元、人民幣及港元計值。由於港元與美元掛鈎，而人民幣兌港元之匯率於期內相對穩定，故本集團之潛在外幣風險相對有限。

僱員及薪酬政策

於二零二三年六月三十日，本集團有30名(二零二二年十二月三十一日：30名)僱員。本集團給予僱員之薪酬大致上按彼等之表現及經驗而定，並參考行業內目前慣例。僱員薪酬待遇包括薪金、保險、強制性公積金及購股權計劃。其他僱員福利包括醫療保障、房屋津貼及酌情花紅。

中期股息

本公司董事會(「董事會」)不建議就截至二零二三年六月三十日止六個月派付中期股息(二零二二年六月三十日：無)。

Corporate Governance and Other Information

企業管治及其他資料

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 30 June 2023, the interests or short positions of the Directors and the chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers ("Model Code") were as follows.

Long positions

Shares and underlying shares of the Company

Name of Director	Capacity	Number of underlying shares held	Approximate percentage of the issued share capital of the Company (Note 1) 佔本公司已發行股本之概約百分比 (附註1)
董事姓名	身份	所持相關股份數目	
Mr. Zhang Hengxin	Beneficial owner	3,724,000 (Note 2)	0.38%
張亨鑫先生	實益擁有人	(附註2)	
Mr. Jia Minghui	Beneficial owner	3,724,000 (Note 2)	0.38%
賈明暉先生	實益擁有人	(附註2)	
Mr. Au Yeung Ming Yin Gordon	Beneficial owner	3,724,000 (Note 2)	0.38%
歐陽銘賢先生	實益擁有人	(附註2)	

Notes:

- The calculation of percentage figures is based on the relevant number of shares as a percentage of the number of shares of the Company in issue as at 30 June 2023.
- These underlying shares are share options granted by the Company on 4 May 2020 under the share option scheme of the Company at the exercise price of HK\$0.435 per share.

董事及最高行政人員於本公司及其相聯法團的股份、相關股份及債權證的權益及淡倉

於二零二三年六月三十日，本公司董事及最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例（「證券及期貨條例」）第XV部的股份、相關股份及債權證中擁有登記於根據證券及期貨條例第352條由本公司存置的登記冊，或根據上市發行人董事進行證券交易之標準守則（「標準守則」）須另行知會本公司及香港聯合交易所有限公司（「聯交所」）的權益或淡倉如下。

好倉

本公司股份及相關股份

Name of Director	Capacity	Number of underlying shares held	Approximate percentage of the issued share capital of the Company (Note 1) 佔本公司已發行股本之概約百分比 (附註1)
董事姓名	身份	所持相關股份數目	
Mr. Zhang Hengxin	Beneficial owner	3,724,000 (Note 2)	0.38%
張亨鑫先生	實益擁有人	(附註2)	
Mr. Jia Minghui	Beneficial owner	3,724,000 (Note 2)	0.38%
賈明暉先生	實益擁有人	(附註2)	
Mr. Au Yeung Ming Yin Gordon	Beneficial owner	3,724,000 (Note 2)	0.38%
歐陽銘賢先生	實益擁有人	(附註2)	

附註：

- 百分比數字乃按相關股份數目佔本公司於二零二三年六月三十日已發行股份數目之百分比計算。
- 該等相關股份為本公司根據本公司購股權計劃於二零二零年五月四日按行使價每股0.435港元授出的購股權。

SHARE OPTIONS

On 30 June 2015, the Company adopted a share option scheme (“Share Option Scheme”), which was approved by the shareholders of the Company (“Shareholders”) at the annual general meeting of the Company held on the same date.

The purpose of the Share Option Scheme is to enable the Group to grant share options to the eligible participants as incentives or rewards for their contributions to the Group.

According to the Share Option Scheme, the Board may grant share options to the following persons or entities (“Eligible Participants”) to subscribe for such number of shares as the Board may determine in accordance with the provisions of the Share Option Scheme and the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”):

- (1) any employee (whether full time or part time, including any executive director but excluding any non-executive director) of the Company, any subsidiary of the Company or any entity in which any member of the Group holds any equity interest (“Invested Entity”);
- (2) any non-executive directors (including independent non-executive directors) of the Company, any subsidiary of the Company or any Invested Entity;
- (3) any supplier of goods or services to any member of the Group or any Invested Entity;
- (4) any customer of any member of the Group or any Invested Entity;
- (5) any person or entity that provides research, development or other technical support to any member of the Group or any Invested Entity;
- (6) any shareholder of any member of the Group or any Invested Entity or any holder of any securities issued by any member of the Group or any Invested Entity;

購股權

於二零一五年六月三十日，本公司採納一項購股權計劃（「購股權計劃」），其由本公司股東（「股東」）於在同日舉行之本公司股東週年大會上批准。

購股權計劃旨在使本集團可向合資格參與者授出購股權，作為彼等對本集團作出貢獻之獎勵或回報。

根據購股權計劃，董事會可向以下人士或實體（「合資格參與者」）授出購股權，以認購董事會根據購股權計劃之條文及聯交所證券上市規則（「上市規則」）可能釐定數目之股份：

- (1) 本公司、本公司任何附屬公司或本集團任何成員公司持有任何股權的任何實體（「所投資實體」）的任何僱員（不論全職或兼職，包括任何執行董事，但不包括任何非執行董事）；
- (2) 本公司、本公司任何附屬公司或任何所投資實體的任何非執行董事（包括獨立非執行董事）；
- (3) 本集團任何成員公司或任何所投資實體的任何貨物或服務供應商；
- (4) 本集團任何成員公司或任何所投資實體的任何客戶；
- (5) 為本集團任何成員公司或任何所投資實體提供研究、開發或其他技術支持的任何人士或實體；
- (6) 本集團任何成員公司或任何所投資實體的任何股東或本集團任何成員公司或任何所投資實體所發行任何證券的任何持有人；

SHARE OPTIONS (continued)

- (7) any adviser (professional or otherwise) or consultant to any area of business or business development of any member of the Group or any Invested Entity;
- (8) any other group or classes of participants who have contributed or may contribute by way of joint venture, business alliance or other business arrangement to the development and growth of the Group; and
- (9) any company wholly owned by one or more Eligible Participants.

Share options granted should be accepted within 28 days from the date of the letter of grant. Upon acceptance of the share options, the grantee shall pay HK\$1.00 to the Company by way of consideration for the grant. Subject to the terms of the Share Option Scheme and all applicable laws, the Board has the power to determine the period within which payments or calls must or may be made.

The exercise price of share options shall be determined by the Board, which shall be at least the highest of (i) the closing price of the shares as stated in the daily quotations sheet of the Stock Exchange on the date of the grant, which must be a business day; (ii) the average closing price of the shares as stated in the daily quotations sheets of the Stock Exchange for the five business days immediately preceding the date of the grant; and (iii) the nominal value of a share.

The maximum number of shares which may be issued upon the exercise of all share options to be granted under the Share Option Scheme and any other share option scheme(s) of the Company must not exceed 10% of the issued share capital of the Company on the date of approval and adoption of the Share Option Scheme provided that the Company may at any time seek approval from the Shareholders to refresh the limit to 10% of the shares in issue as at the date of approval by the Shareholders in general meeting where such limit is refreshed. Share options previously granted under any share option schemes of the Company (including those outstanding, cancelled, lapsed in accordance with such schemes or exercised options) will not be counted for the purpose of calculating the limit as refreshed.

購股權 (續)

- (7) 本集團任何成員公司或任何所投資實體在任何業務範疇或業務發展的任何諮詢人士(專業或其他人士)或顧問;
- (8) 透過合資經營、業務聯盟或其他業務安排對本集團發展及增長已作出或可能作出貢獻的任何其他參與者群體或類別;及
- (9) 由一名或多名合資格參與者全資擁有的任何公司。

授出之購股權須於由授出函件日期起計28日內接納。於接納購股權時，承授人應就授出之購股權向本公司支付1.00港元作為代價。在購股權計劃條款及所有適用法律之規限下，董事會有權釐定必須或可以繳付或催繳款項之期限。

購股權之行使價由董事會決定，惟不得少於以下之最高者：(i)於授出日期(必須為營業日)聯交所每日報價表所報之股份收市價；(ii)於緊接授出日期前五個營業日聯交所每日報價表所報之股份平均收市價；及(iii)股份面值。

因行使根據購股權計劃及本公司任何其他購股權計劃將予授出之所有購股權而可予發行之股份數目上限，不得超過於批准及採納購股權計劃當日本公司已發行股本之10%，惟本公司可隨時徵求股東批准將上限更新至股東於股東大會上批准更新上限當日已發行股份之10%。就計算經更新上限而言，先前根據本公司任何購股權計劃授出之購股權(包括根據有關計劃尚未行使、已註銷、已失效或已行使之購股權)均不予計算。

SHARE OPTIONS *(continued)*

The total number of shares issued and may fall to be issued upon exercise of the share options granted under the Share Option Scheme and any other share option scheme(s) of the Company (including exercised, cancelled and outstanding options) to each eligible participant in any 12-month period up to and including the date of grant shall not exceed 1% of the shares in issue as at the date of grant unless such grant has been duly approved by ordinary resolution of the Shareholders in general meeting at which the relevant eligible participant and his associates abstained from voting. Share options granted to substantial Shareholders or Independent Non-executive Directors or any of their respective associates in any 12-month period in excess of 0.1% of the Company's issued share capital on the date of grant and with a value in excess of HK\$5 million must be approved in advance by the Shareholders.

The period during which a share option may be exercised will be determined by the Board at its absolute discretion, save that no share option can be exercised more than 10 years after it has been granted. There is no general requirement that a share option must be held for any minimum period before it can be exercised. The Share Option Scheme is valid and effective for a period of ten years and will expire at the close of business on 29 June 2025.

At the annual general meeting of the Company held on 30 June 2022, the Company was authorised to refresh the scheme mandate limit to issue a maximum of 48,377,589 share options under the Share Option Scheme. Notwithstanding the forgoing, the shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the Share Option Scheme and any other share option schemes of the Company at any time shall not exceed 30% of the shares in issue from time to time.

購股權 (續)

截至授出日期(包括該日)止任何12個月期間,因行使根據購股權計劃及本公司任何其他購股權計劃授出之購股權(包括已行使、已註銷及尚未行使之購股權)而已發行及可能須發行予各合資格參與者之股份總數,不得超過授出當日已發行股份之1%,惟該授出已於股東大會上獲股東以普通決議案方式正式批准則屬例外,而相關合資格參與者及其聯繫人須於會上放棄投票。倘於任何12個月期間向主要股東或獨立非執行董事或彼等各自之任何聯繫人授出之購股權多於授出日期本公司已發行股本之0.1%,且價值高於5,000,000港元,則必須事先經股東批准。

購股權之行使期將由董事會全權酌情決定,惟不得於授出起計10年後行使。並無行使購股權前必須持有購股權之任何最短期限之一般規定。購股權計劃於10年內有效及生效,並將於二零二五年六月二十九日營業時間結束時屆滿。

於二零二二年六月三十日舉行之本公司股東週年大會上,本公司獲授權更新計劃授權上限以根據購股權計劃發行最多48,377,589份購股權。儘管上述者,因行使根據購股權計劃及本公司任何其他購股權計劃已授出但有待行使之所有尚未行使購股權而可能發行之股份於任何時候不得超過不時已發行股份之30%。

SHARE OPTIONS (continued)

購股權 (續)

The following table discloses movements in the Company's share options under the Share Option Scheme during the six months ended 30 June 2023:

下表披露截至二零二三年六月三十日止六個月本公司購股權計劃項下之購股權變動：

Date of grant	Exercise price	Exercise period	Vesting period	Outstanding at 1 January 2023 於二零二三年一月一日尚未行使	Granted during the period 於期內已授出	Exercised during the period 於期內已行使	Lapsed/ Forfeited during the period 於期內已失效/沒收	Outstanding at 30 June 2023 於二零二三年六月三十日尚未行使
授出日期	行使價 HK\$ 港元	行使期	歸屬期					
Directors								
董事								
Zhang Hengxin	4 May 2020	0.435	From 4 May 2020 to 3 May 2025	No	3,724,000	-	-	3,724,000
張亨鑫	二零二零年五月四日		二零二零年五月四日至二零二五年五月三日	無				
Jia Minghui	4 May 2020	0.435	From 4 May 2020 to 3 May 2025	No	3,724,000	-	-	3,724,000
賈明暉	二零二零年五月四日		二零二零年五月四日至二零二五年五月三日	無				
Au Yeung Ming Yin Gordon	4 May 2020	0.435	From 4 May 2020 to 3 May 2025	No	3,724,000	-	-	3,724,000
歐陽銘賢	二零二零年五月四日		二零二零年五月四日至二零二五年五月三日	無				
Employees								
僱員								
	4 May 2020	0.435	From 4 May 2020 to 3 May 2025	No	26,068,000	-	-	26,068,000
	二零二零年五月四日		二零二零年五月四日至二零二五年五月三日	無				
	21 April 2022	0.373	From 21 April 2022 to 20 April 2027	No	48,360,000	-	-	48,360,000
	二零二二年四月二十一日		二零二二年四月二十一日至二零二七年四月二十日	無				
					85,600,000	-	-	85,600,000

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 30 June 2023, so far as is known to the Directors and the chief executive of the Company, no persons or corporations (other than Directors or chief executive of the Company) had, or deemed or taken to have, interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO, or who were directly or indirectly, interested in 5% or more of the number of any class of shares in issue of the Company, carrying the rights to vote in all circumstances at general meetings of the Company.

主要股東及其他人士於本公司股份及相關股份之權益及淡倉

於二零二三年六月三十日，據本公司董事及最高行政人員所知，概無人士或公司（本公司董事或最高行政人員除外）已或被當作或視為於本公司股份或相關股份中，擁有已記入本公司根據證券及期貨條例第336條須存置之登記冊內之權益或淡倉，或直接或間接擁有附帶權利可於任何情況下在本公司股東大會上投票之本公司任何類別已發行股份數目5%或以上權益。

CORPORATE GOVERNANCE

The Company has complied with all code provisions of the Corporate Governance Code (“CG Code”) as set out in Appendix 14 to the Listing Rules for the six months ended 30 June 2023, save as disclosed as follows.

Code provision A.2.1 of the CG Code requires the roles of chairman and chief executive should be separate and should not be performed by the same individual.

Mr. Zhang Hengxin was the Chairman and the Managing Director of the Company (the Company regards the role of its managing director to be the same as that of chief executive under the CG Code) during the six months ended 30 June 2023. During the period under review, the Group has been streamlining its operations, including business development, operation efficiency and financial management. The Board considers that it would be in the best interest of the Shareholders that the roles of the Chairman and the Managing Director of the Company be combined to enable a strong and dedicated leadership to reposition the Company and implement effective measures to improve Shareholders’ value. In this light, the Company has maintained Mr. Zhang Hengxin as the Chairman and the Managing Director of the Company. The Company will review the current structure when and as it becomes appropriate.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code set out in Appendix 10 to the Listing Rules as the code of conduct regarding securities transactions by its Directors. Having made specific enquiry, all Directors have confirmed that they have fully complied with the required standard set out in the Model Code during the six months ended 30 June 2023.

企業管治

除下文所披露者外，於截至二零二三年六月三十日止六個月，本公司一直遵守上市規則附錄十四所載之企業管治守則（「企業管治守則」）之所有守則條文。

企業管治守則之守則條文第A.2.1條規定，主席與行政總裁之角色應有區分，並不應由一人同時兼任。

於截至二零二三年六月三十日止六個月，張亨鑫先生同時擔任本公司主席兼董事總經理（本公司視其董事總經理一職相當於企業管治守則所指之行政總裁）。於回顧期間內，本集團一直精簡業務，包括業務發展、營運效率及財務管理。董事會認為本公司主席與董事總經理之職務合併符合股東之最佳利益，此舉有助於通過強大而專注之領導將本公司重新定位並實施有效措施以提升股東價值。有鑒於此，本公司仍由張亨鑫先生擔任本公司主席兼董事總經理。本公司將於適當時候檢討目前架構。

董事進行證券交易的標準守則

本公司已採納上市規則附錄十所載之標準守則作為其董事進行證券交易之行為守則。經作出特定查詢後，全體董事已確認彼等於截至二零二三年六月三十日止六個月全面遵守標準守則所載之規定標準。

Corporate Governance and Other Information 企業管治及其他資料

AUDIT COMMITTEE

The audit committee of the Company (“Audit Committee”) comprises three Independent Non-executive Directors, namely Mr. Au Yeung Ming Yin Gordon (chairman of the Audit Committee), Ms. Ye Mengmei and Mr. Guo Zhenhui. The Audit Committee has reviewed with the management the accounting principles and practices adopted by the Group, and discussed financial reporting matters including the review of the unaudited interim results for the six months ended 30 June 2023.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES

During the six months ended 30 June 2023, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed securities.

By order of the Board

AMCO United Holding Limited

Zhang Hengxin

Chairman and Managing Director

Hong Kong, 28 August 2023

審核委員會

本公司審核委員會（「審核委員會」）由三名獨立非執行董事歐陽銘賢先生（審核委員會主席）、葉夢美女士及郭鎮輝先生組成。審核委員會已聯同管理層審閱本集團所採納之會計原則及慣例，並就財務報告事宜（包括審閱截至二零二三年六月三十日止六個月之未經審核中期業績）進行討論。

購買、出售或贖回本公司上市證券

於截至二零二三年六月三十日止六個月，本公司及其任何附屬公司概無購買、出售或贖回本公司任何上市證券。

承董事會命

雋泰控股有限公司

主席兼董事總經理

張亨鑫

香港，二零二三年八月二十八日

Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

簡明綜合中期損益及其他全面收益表

For the six months ended 30 June 2023 截至二零二三年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月		
		2023	2022	
		Unaudited	Unaudited	
		HK\$'000	HK\$'000	
		二零二三年	二零二二年	
		未經審核	未經審核	
		千港元	千港元	
	Notes 附註			
Revenue	收入	3	23,259	25,030
Cost of sales and services	銷售及服務成本		(18,353)	(17,959)
Gross profit	毛利		4,906	7,071
Other income and other gains or losses	其他收入及其他收益或虧損	4	(20,312)	(10,604)
Distribution costs	分銷成本		(2,738)	(3,180)
Administrative expenses	行政開支		(10,110)	(21,700)
Finance costs	財務費用	5	(1,419)	(1,788)
Loss before income tax	除所得稅前虧損	6	(29,673)	(30,201)
Income tax credit	所得稅抵免	7	-	-
Loss for the period	期內虧損		(29,673)	(30,201)
Other comprehensive income/(loss) for the period:	期內其他全面收益/(虧損):			
<i>Item that may be reclassified subsequently to profit or loss:</i>	<i>其後可重新分類至損益之項目:</i>			
Exchange differences on translating foreign operations	換算海外業務產生之匯兌差額		27	87
Total comprehensive loss for the period attributable to owners of the Company	本公司擁有人應佔期內全面虧損總額		(29,646)	(30,114)
Loss per share	每股虧損			
Basic and diluted	基本及攤薄	9	HK(3.36) cent港仙	HK(6.24) cent港仙 (Restated) (經重列)

Interim Condensed Consolidated Statement of Financial Position

簡明綜合中期財務狀況表

As at 30 June 2023 於二零二三年六月三十日

		Notes	30 June 2023 Unaudited HK\$'000 二零二三年 六月三十日 未經審核 千港元	31 December 2022 Audited HK\$'000 二零二二年 十二月三十一日 經審核 千港元
		附註		
ASSETS AND LIABILITIES	資產及負債			
Non-current assets	非流動資產			
Property, plant and equipment	物業、廠房及設備	10	934	1,074
Equity instrument at fair value through profit or loss	透過損益按公允價值列賬之權益工具		5,272	5,272
			6,206	6,346
Current assets	流動資產			
Inventories	存貨		425	2
Held-for-trading investments	持作買賣投資	11	23,893	36,029
Trade and other receivables	貿易及其他應收款項	12	120,910	126,741
Cash and cash equivalents	現金及現金等價物		10,840	3,722
			156,068	166,494
Current liabilities	流動負債			
Trade and other payables	貿易及其他應付款項	13	95,409	99,011
Lease liabilities	租賃負債		223	223
			95,632	99,234
Net current assets	流動資產淨值		60,436	67,260
Total assets less current liabilities	資產總值減流動負債		66,642	73,606
Non-current liabilities	非流動負債			
Bond payables	應付債券		30,000	30,900
Lease liabilities	租賃負債		104	215
Financial liabilities at fair value through profit or loss	透過損益按公允價值列賬之財務負債		–	23,902
			30,104	55,017
Net assets	資產淨值		36,538	18,589
EQUITY	權益			
Share capital	股本	14	48,378	24,189
Reserves	儲備		(11,840)	(5,600)
Total equity	權益總額		36,538	18,589

Interim Condensed Consolidated Statement of Changes in Equity

簡明綜合中期權益變動表

For the six months ended 30 June 2023 截至二零二三年六月三十日止六個月

		Share capital	Share premium	Share option reserve	Translation reserve	Accumulated losses	Total
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		股本	股份溢價	購股權儲備	匯兌儲備	累計虧損	總計
		千港元	千港元	千港元	千港元	千港元	千港元
At 1 January 2023 (audited)	於二零二三年一月一日 (經審核)	24,189	457,234	14,277	2,069	(479,180)	18,589
Loss and total comprehensive loss for the period	期內虧損及全面虧損總額	-	-	-	27	(29,673)	(29,646)
Right issue of shares	供股	24,189	23,406	-	-	-	47,595
At 30 June 2023 (unaudited)	於二零二三年六月三十日 (未經審核)	48,378	480,640	14,277	2,096	(508,853)	36,538
At 1 January 2022 (audited)	於二零二二年一月一日 (經審核)	24,189	457,234	8,819	3,262	(378,680)	114,824
Loss and total comprehensive loss for the period	期內虧損及全面虧損總額	-	-	-	87	(30,201)	(30,114)
Issue of share options	發行購股權	-	-	9,205	-	-	9,205
Lapse of share options	購股權失效	-	-	(3,751)	-	3,751	-
At 30 June 2022 (unaudited)	於二零二二年六月三十日 (未經審核)	24,189	457,234	14,273	3,349	(405,130)	93,915

Interim Condensed Consolidated Statement of Cash Flows

簡明綜合中期現金流量表

For the six months ended 30 June 2023 截至二零二三年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月	
		2023 Unaudited HK\$'000 二零二三年 未經審核 千港元	2022 Unaudited HK\$'000 二零二二年 未經審核 千港元
Net cash used in operating activities	經營活動動用之現金淨額	(8,423)	(18,176)
Net cash generated from/(used in) investing activities	投資活動產生／(動用)之現金淨額	1,342	(1,452)
Net cash generated from/(used in) financing activities	融資活動產生／(動用)之現金淨額	14,199	16,213
Net increase/(decrease) in cash and cash equivalents	現金及現金等價物增加／(減少)淨額	7,118	(3,415)
Cash and cash equivalents at 1 January	於一月一日之現金及現金等價物	3,722	4,721
Cash and cash equivalents at 30 June	於六月三十日之現金及現金等價物	10,840	1,306
Represented by:	為：		
Cash and bank balances	現金及銀行結餘	10,840	1,306

Notes to the Interim Condensed Consolidated Financial Statements

簡明綜合中期財務報表附註

1. GENERAL INFORMATION

AMCO United Holding Limited (the “Company”) was incorporated in Bermuda with limited liability on 19 August 1994 as an exempted company under the Companies Act 1981 of Bermuda with its shares listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) since 28 November 1996.

The Company and its subsidiaries (hereinafter collectively referred to as the “Group”) are principally engaged in (i) manufacture and sale of medical devices products; (ii) manufacture and sale of plastic moulding products; (iii) provision of construction services in building construction, building maintenance and improvement works, project management, renovation and decoration works; (iv) provision of money lending; and (v) investment in securities.

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

The interim condensed consolidated financial statements for the six months ended 30 June 2023 have been prepared in accordance with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on the Stock Exchange and with the Hong Kong Accounting Standard 34 “Interim Financial Reporting”, issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”). The interim condensed consolidated financial statements are unaudited but have been reviewed by the Company’s audit committee.

The interim condensed consolidated financial statements should be read in conjunction with the Group’s annual financial statements for the year ended 31 December 2022, which have been prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”).

1. 一般資料

雋泰控股有限公司(「本公司」)於一九九四年八月十九日根據百慕達一九八一年公司法在百慕達註冊成立為一間獲豁免有限公司，其股份自一九九六年十一月二十八日起於香港聯合交易所有限公司(「聯交所」)主板上市。

本公司及其附屬公司(以下統稱為「本集團」)主要從事(i)製造及銷售醫療設備產品；(ii)製造及銷售塑膠模具產品；(iii)提供樓宇建造、樓宇維修及改善工程、項目管理、裝修及裝飾工程方面之建造服務；(iv)提供放貸；及(v)證券投資。

2. 編製基準及會計政策

截至二零二三年六月三十日止六個月之簡明綜合中期財務報表乃按照聯交所證券上市規則附錄十六之適用披露規定，以及香港會計師公會(「香港會計師公會」)頒佈之香港會計準則第34號「中期財務報告」編製。簡明綜合中期財務報表為未經審核，惟已由本公司之審核委員會審閱。

簡明綜合中期財務報表應與本集團按照香港財務報告準則(「香港財務報告準則」)編製之截至二零二二年十二月三十一日止年度之年度財務報表一併閱讀。

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES *(continued)*

The interim condensed consolidated financial statements have been prepared under the historical cost basis except for certain financial instruments which are measured at their fair value.

The accounting policies adopted and methods of computation used in the interim condensed consolidated financial statements are the same as those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2022.

In the current interim period, the Group has adopted all the new and revised standard, amendments and interpretation ("new and revised HKFRSs") issued by the HKICPA that are relevant to its operations and effective for its accounting period beginning on 1 January 2023. The adoption of these new and revised HKFRSs did not result in significant changes to the Group's accounting policies and amounts reported for the current and prior accounting period.

The Group has not early applied any new and revised HKFRSs that are not yet effective for the current period.

3. SEGMENT INFORMATION

The Group determines its operating segments based on the reports reviewed by the chief operating decision maker that are used to make strategic decisions.

2. 編製基準及會計政策 (續)

簡明綜合中期財務報表已按歷史成本基準編製，惟按其公允價值計量之若干財務工具除外。

簡明綜合中期財務報表內採納之會計政策及所使用之計算方法與本集團編製截至二零二二年十二月三十一日止年度之年度財務報表所依循者一致。

於本中期期間，本集團已採納由香港會計師公會頒佈並與其營運有關及於其會計期間（於二零二三年一月一日開始）生效之所有新訂及經修訂準則、修訂及詮釋（「新訂及經修訂香港財務報告準則」）。採納該等新訂及經修訂香港財務報告準則並無令本集團之會計政策以及就本會計期間及過往會計期間呈報之數額出現重大變動。

本集團並未提早應用任何於本期間尚未生效之新訂及經修訂香港財務報告準則。

3. 分部資料

本集團按主要經營決策者所審閱並賴以作出戰略決策之報告釐定其經營分部。

3. SEGMENT INFORMATION (continued)

The Group has five (30 June 2022: five) reportable segments. The segments are managed separately as each business offers different products and services and requires different business strategies. The following summary describes the operations in each of the Group's reportable segments:

- (1) Manufacture and sale of medical devices products ("Medical Products Business");
- (2) Manufacture and sale of plastic moulding products ("Plastic Products Business");
- (3) Provision of construction services in building construction, building maintenance and improvement works, project management, renovation and decoration works ("Building Contract Works Business");
- (4) Provision of money lending ("Money Lending Business"); and
- (5) Investment in securities ("Securities Investment").

Inter-segment transactions, if any, are priced with reference to prices charged to external parties for similar products and services. Corporate revenue and expenses are not allocated to the operating segments as they are not included in the measure of the segments' profit/loss that is used by the chief operating decision maker for assessment of segment performance.

3. 分部資料 (續)

本集團有五個(二零二二年六月三十日:五個)可報告分部。由於各業務提供不同產品及服務及所需之業務策略亦不盡相同,因此各分部之管理工作乃獨立進行。以下為本集團各可報告分部業務之概要:

- (1) 製造及銷售醫療設備產品(「醫療產品業務」);
- (2) 製造及銷售塑膠模具產品(「塑膠產品業務」);
- (3) 提供樓宇建造、樓宇維修及改善工程、項目管理、裝修及裝飾工程方面之建造服務(「樓宇承包工程業務」);
- (4) 提供放貸(「放貸業務」);及
- (5) 證券投資(「證券投資」)。

分部間交易(如有)之價格乃參考就類似產品及服務向外部人士收取之價格釐定。由於企業收入及開支並未計入主要經營決策者評估分部表現時使用之分部溢利/虧損計量內,故並無分配至各經營分部。

Notes to the Interim Condensed Consolidated Financial Statements 簡明綜合中期財務報表附註

3. SEGMENT INFORMATION (continued)

The following is an analysis of the Group's revenue and results by reportable segment:

Six months ended 30 June 2023 (Unaudited)

		Medical Devices Business HK\$'000 醫療 設備業務 千港元	Plastic Moulding Business HK\$'000 塑膠 模具業務 千港元	Building Contract Works Business HK\$'000 樓宇承包 工程業務 千港元	Money Lending Business HK\$'000 放貸業務 千港元	Securities Investment HK\$'000 證券投資 千港元	Total HK\$'000 總額 千港元
Revenue from external customers	來自外部客戶收入	16,380	635	250	5,994	-	23,259
Reportable segment revenue	可報告分部收入	16,380	635	250	5,994	-	23,259
Timing of revenue recognition	確認收入的時間						
At a point in time	某一時間點	16,380	635	250	-	-	23,259
Over time	一段時間內	-	-	-	-	-	-
		16,380	635	250	-	-	23,259
Reportable segment profit/(loss)	可報告分部溢利/ (虧損)	1,430	219	(240)	(840)	(11,014)	(10,445)

3. 分部資料 (續)

以下為本集團按可報告分部劃分之收入及業績分析：

截至二零二三年六月三十日止六個月（未經審核）

Notes to the Interim Condensed Consolidated Financial Statements
簡明綜合中期財務報表附註

3. SEGMENT INFORMATION (continued)

Six months ended 30 June 2022 (Unaudited)

		Medical Devices Business HK\$'000 醫療 設備業務 千港元	Plastic Moulding Business HK\$'000 塑膠 模具業務 千港元	Building Contract Works Business HK\$'000 樓宇承包 工程業務 千港元	Money Lending Business HK\$'000 放貸業務 千港元	Securities Investment HK\$'000 證券投資 千港元	Total HK\$'000 總額 千港元
Revenue from external customers	來自外部客戶收入	17,047	1,173	1,283	5,527	–	25,030
Reportable segment revenue	可報告分部收入	17,047	1,173	1,283	5,527	–	25,030
Timing of revenue recognition	確認收入的時間						
At a point in time	某一時間點	17,047	1,173	–	–	–	18,220
Over time	一段時間內	–	–	1,283	–	–	1,283
		17,047	1,173	1,283	–	–	19,503
Reportable segment profit/(loss)	可報告分部溢利/ (虧損)	999	357	(759)	(1,307)	(10,680)	(11,390)

Reportable segment profit/loss represents the profit/loss attributable to each segment without allocation of corporate administrative expenses, corporate directors' emoluments, corporate income, finance costs and income tax credit. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and performance assessment.

3. 分部資料 (續)

截至二零二二年六月三十日止六個月(未經審核)

可報告分部溢利/虧損指各分部應佔之溢利/虧損，當中並無就全體行政開支、全體董事酬金、全體收入、財務成本及所得稅抵免作出分配。此乃向主要經營決策者報告以進行資源分配及表現評估之方法。

Notes to the Interim Condensed Consolidated Financial Statements 簡明綜合中期財務報表附註

3. SEGMENT INFORMATION (continued)

The following is an analysis of the Group's assets and liabilities by reportable segments:

Reportable segment assets and liabilities

		Medical Devices Business HK\$'000 醫療 設備業務 千港元	Plastic Moulding Business HK\$'000 塑膠 模具業務 千港元	Building Contract Works Business HK\$'000 樓宇承包 工程業務 千港元	Money Lending Business HK\$'000 放貸業務 千港元	Securities Investment HK\$'000 證券投資 千港元	Total HK\$'000 總額 千港元
As at 30 June 2023 (unaudited)	於二零二三年六月 三十日(未經審核)						
Reportable segment assets	可報告分部資產	32,897	584	1,020	94,279	28,222	157,002
Reportable segment liabilities	可報告分部負債	63,342	9,070	2,138	940	-	75,490

3. 分部資料 (續)

以下為本集團按可報告分部劃分之資產及負債分析：

可報告分部資產及負債

		Medical Devices Business HK\$'000 醫療 設備業務 千港元	Plastic Moulding Business HK\$'000 塑膠 模具業務 千港元	Building Contract Works Business HK\$'000 樓宇承包 工程業務 千港元	Money Lending Business HK\$'000 放貸業務 千港元	Securities Investment HK\$'000 證券投資 千港元	Total HK\$'000 總額 千港元
As at 31 December 2022 (audited)	於二零二二年 十二月三十一日 (經審核)						
Reportable segment assets	可報告分部資產	34,330	16	1,142	90,654	36,215	162,357
Reportable segment liabilities	可報告分部負債	69,732	5,742	2,486	1,243	-	79,203

Notes to the Interim Condensed Consolidated Financial Statements
簡明綜合中期財務報表附註

3. SEGMENT INFORMATION (continued)

All assets are allocated to reportable segments other than cash and cash equivalents and corporate assets.

All liabilities are allocated to reportable segments other than bond payables and corporate liabilities.

The following is the Group's reconciliation of reportable segment revenue and profit or loss:

3. 分部資料 (續)

所有資產均分配至可報告分部，惟並不包括現金及現金等價物以及全體資產。

所有負債均分配至可報告分部，惟並不包括應付債券及全體負債。

以下為本集團可報告分部收入及損益之對賬：

		Six months ended 30 June	
		截至六月三十日止六個月	
		2023	2022
		Unaudited	Unaudited
		HK\$'000	HK\$'000
		二零二三年	二零二二年
		未經審核	未經審核
		千港元	千港元
Revenue	收入		
Reportable segment revenue	可報告分部收入	23,259	25,030
Consolidated revenue	綜合收入	23,259	25,030
Loss before income tax	除所得稅前虧損		
Reportable segment loss	可報告分部虧損	(10,445)	(11,390)
Finance costs	財務費用	(1,419)	(1,788)
Unallocated corporate income	未分配全體收入	-	-
Unallocated corporate expenses	未分配全體開支	(17,809)	(17,023)
Consolidated loss before income tax	除所得稅前綜合虧損	(29,673)	(30,201)

Notes to the Interim Condensed Consolidated Financial Statements
簡明綜合中期財務報表附註

4. OTHER INCOME AND OTHER GAINS OR LOSSES

4. 其他收入及其他收益或虧損

		Six months ended 30 June	
		截至六月三十日止六個月	
		2023	2022
		Unaudited	Unaudited
		HK\$'000	HK\$'000
		二零二三年	二零二二年
		未經審核	未經審核
		千港元	千港元
Loss on change in fair value of held-for-trading investments	持作買賣投資之公允價值變動虧損	(11,014)	(10,680)
Loss on change in fair value of financial liabilities at fair value through profit or loss	透過損益按公允價值列賬之財務負債之公允價值變動虧損	(9,298)	-
Interest income	利息收入	-	3
Others	其他	-	73
		(20,312)	(10,604)

5. FINANCE COSTS

5. 財務費用

		Six months ended 30 June	
		截至六月三十日止六個月	
		2023	2022
		Unaudited	Unaudited
		HK\$'000	HK\$'000
		二零二三年	二零二二年
		未經審核	未經審核
		千港元	千港元
Interest on bond payables	應付債券利息	1,412	1,781
Interest expense on lease liabilities	租賃負債利息開支	7	7
		1,419	1,788

Notes to the Interim Condensed Consolidated Financial Statements
簡明綜合中期財務報表附註

6. LOSS BEFORE INCOME TAX

6. 除所得稅前虧損

		Six months ended 30 June 截至六月三十日止六個月	
		2023	2022
		Unaudited HK\$'000	Unaudited HK\$'000
		二零二三年 未經審核 千港元	二零二二年 未經審核 千港元
Loss before income tax has been arrived at after charging:	除所得稅前虧損已扣除下列各項後達至：		
Staff costs (including directors' emoluments)	僱員成本（包括董事酬金）		
– Salaries, wages and other benefits	– 薪金、工資及其他福利	1,690	1,624
– Contributions to defined contribution retirement plan	– 界定供款退休計劃供款	48	48
– Share-based payment expenses	– 以股份為基礎之付款開支	–	9,205
		1,738	10,877
Depreciation of property, plant and equipment	物業、廠房及設備折舊	140	246
Net impairment loss on trade and other receivables	貿易及其他應收款項之減值虧損淨額	–	490
Cost of inventories recognised as expenses	確認為開支之存貨成本	17,908	16,865
Cost of services	服務成本	445	1,094

7. INCOME TAX CREDIT

7. 所得稅抵免

		Six months ended 30 June 截至六月三十日止六個月	
		2023	2022
		Unaudited HK\$'000	Unaudited HK\$'000
		二零二三年 未經審核 千港元	二零二二年 未經審核 千港元
Deferred tax credit – current period	遞延稅項抵免 – 本期間	–	–

Hong Kong Profits Tax is calculated at 16.5% of the estimated assessable profits for both periods. No Hong Kong Profits Tax was provided for both periods as members of the Group did not derive any estimated assessable profits or had sufficient tax losses brought forward to offset against the estimated assessable profits for the periods ended 30 June 2023 and 2022.

香港利得稅乃按兩個期間之估計應課稅溢利之16.5%計算。由於本集團之成員公司於截至二零二三年及二零二二年六月三十日止期間並無取得任何估計應課稅溢利或並不具備充足的結轉稅項虧損以抵銷估計應課稅溢利，故於兩個期間並無作出香港利得稅撥備。

Notes to the Interim Condensed Consolidated Financial Statements 簡明綜合中期財務報表附註

8. INTERIM DIVIDEND

No dividends were paid, declared or proposed during the reporting period. The board of directors of the Company does not recommend the payment of an interim dividend for the six months ended 30 June 2023 and 2022.

9. LOSS PER SHARE

(a) Basic loss per share

The calculation of the basic loss per share attributable to owners of the Company is based on the following data:

8. 中期股息

報告期內並無派付、宣派或建議派付任何股息。本公司董事會不建議就截至二零二三年及二零二二年六月三十日止六個月派付中期股息。

9. 每股虧損

(a) 每股基本虧損

本公司擁有人應佔每股基本虧損乃基於以下數據計算：

		Six months ended 30 June 截至六月三十日止六個月	
		2023 Unaudited HK\$'000 二零二三年 未經審核 千港元	2022 Unaudited HK\$'000 二零二二年 未經審核 千港元
Loss	虧損		
Loss for the period for the purpose of computation of basic loss per share	就計算每股基本虧損而言之期內虧損	(29,673)	(30,201)
Number of shares	股份數目		
Weighted average number of ordinary shares in issue	已發行普通股之加權平均數	884,235	483,776 (Restated) (經重列)

9. LOSS PER SHARE (continued)

(b) Diluted loss per share

Diluted loss per share was the same as basic loss per share because there was no potential dilutive ordinary share in issue for the six months ended 30 June 2023 and 2022.

The Company's outstanding share options as at 30 June 2023 and 2022 were not taken into account as they had an antidilutive effect for the six months ended 30 June 2023 and 2022 which would result in a reduction in the loss per share.

In August 2022, the Company completed the share consolidation of every five shares into one consolidated share. Accordingly, the weighted average number of shares for the purposes of basic and diluted loss per share has been adjusted for the six months ended 30 June 2022.

10. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2023, the Group incurred depreciation charge on property, plant and equipment of approximately HK\$140,000 (six months ended 30 June 2022: HK\$246,000).

11. HELD-FOR-TRADING INVESTMENTS

The amount represents equity securities listed in Hong Kong. These investments are classified as financial assets at fair value through profit or loss.

9. 每股虧損 (續)

(b) 每股攤薄虧損

因截至二零二三年及二零二二年六月三十日止六個月並無已發行具潛在攤薄影響之普通股，故每股攤薄虧損與每股基本虧損相同。

並無計及本公司於二零二三年及二零二二年六月三十日之尚未行使之購股權，原因為其於截至二零二三年及二零二二年六月三十日止六個月具有反攤薄影響，從而導致每股虧損減少。

於二零二二年八月，本公司完成每五股股份合併為一股合併股份之股份合併。因此，截至二零二二年六月三十日止六個月，就計算每股基本及攤薄虧損之股份加權平均數已進行調整。

10. 物業、廠房及設備之變動

截至二零二三年六月三十日止六個月，本集團物業、廠房及設備產生折舊開支約140,000港元（截至二零二二年六月三十日止六個月：246,000港元）。

11. 持作買賣投資

有關金額為於香港上市之股本證券。該等投資分類為透過損益按公允價值列賬之財務資產。

Notes to the Interim Condensed Consolidated Financial Statements
簡明綜合中期財務報表附註

12. TRADE AND OTHER RECEIVABLES

12. 貿易及其他應收款項

		30 June 2023 Unaudited HK\$'000 二零二三年 六月三十日 未經審核 千港元	31 December 2022 Audited HK\$'000 二零二二年 十二月三十一日 經審核 千港元
Trade receivables from contracts with customers	來自客戶合約之貿易應收款項	55,083	63,765
Less: Allowance for credit losses	減：信貸虧損撥備	(29,050)	(29,050)
		26,033	34,715
Retention receivables from contracts with customers	來自客戶合約之應收保固金	272	272
Less: Allowance for credit losses	減：信貸虧損撥備	(2)	(2)
		270	270
Loan receivables	應收貸款	172,092	167,930
Less: Allowance for credit losses	減：信貸虧損撥備	(77,813)	(77,813)
		94,279	90,117
Deposits, prepayments and other receivables	按金、預付款項及其他應收款項	328	1,639
Total trade and other receivables	貿易及其他應收款項總額	120,910	126,741

Notes to the Interim Condensed Consolidated Financial Statements
簡明綜合中期財務報表附註

12. TRADE AND OTHER RECEIVABLES *(continued)*

The Group allows credit period up to 90 days (31 December 2022: 90 days) to its trade customers. The ageing analysis of trade receivables (net of accumulated impairment losses) by invoice date is as follows:

		30 June 2023 Unaudited HK\$'000 二零二三年 六月三十日 未經審核 千港元	31 December 2022 Audited HK\$'000 二零二二年 十二月三十一日 經審核 千港元
Within 3 months	3個月內	1,889	21,235
Over 3 months but within 6 months	3個月以上但6個月內	1,938	13,043
Over 6 months	6個月以上	22,206	437
		26,033	34,715

Retention receivables are derived from the Building Contract Works Business and are interest-free and recoverable at the end of the retention period of individual construction contracts ranging from 3 months to 1 year.

Loan receivables represent outstanding principals and interest receivables arising from the Money Lending Business of the Group. All of the loan receivables are entered with contractual maturity within 12 months. The Group seeks to maintain strict control over its loan receivables in order to minimise credit risk by reviewing the borrowers' financial positions.

The loan receivables are interest-bearing at rates mutually agreed between the contracting parties, ranging from 4% to 12% per annum (31 December 2022: 4% to 12% per annum).

12. 貿易及其他應收款項 (續)

本集團給予其貿易客戶之信貸期最多為90天(二零二二年十二月三十一日:90天)。貿易應收款項(扣除累計減值虧損)按發票日期劃分之賬齡分析如下:

應收保固金乃來自樓宇承包工程業務並為免息及於各建築合約保固期(介乎三個月至一年)末可予收回。

應收貸款指本集團放貸業務產生之未償還本金及應收利息。所有應收貸款之合約到期日均為12個月內。本集團致力透過審閱借款人之財務狀況,維持對其應收貸款之嚴格控制,務求將信貸風險減至最低。

應收貸款乃按合約方互相協定之利率計息,年利率介乎4%至12%(二零二二年十二月三十一日:年利率4%至12%)。

Notes to the Interim Condensed Consolidated Financial Statements
簡明綜合中期財務報表附註

13. TRADE AND OTHER PAYABLES

13. 貿易及其他應付款項

		30 June	31 December
		2023	2022
		Unaudited	Audited
		HK\$'000	HK\$'000
		二零二三年	二零二二年
		六月三十日	十二月三十一日
		未經審核	經審核
		千港元	千港元
Trade payables	貿易應付款項	58,416	61,010
Retention payables	應付保固金	958	958
Contract liabilities	合約負債	5,002	5,007
Amount due to Titron Group Holdings Limited	應付Titron Group Holdings Limited之款項	1,700	1,700
Amount due to the vendors	應付賣方之款項	7,500	7,500
Accruals and other payables	應計款項及其他應付款項	21,833	22,836
		95,409	99,011

The following is an ageing analysis of trade payables presented based on the invoice date at the end of the reporting period.

於報告期末，貿易應付款項按發票日期呈列之賬齡分析如下。

		30 June	31 December
		2023	2022
		Unaudited	Audited
		HK\$'000	HK\$'000
		二零二三年	二零二二年
		六月三十日	十二月三十一日
		未經審核	經審核
		千港元	千港元
Within 3 months	3個月內	1,380	-
Over 3 months but within 6 months	3個月以上但6個月內	-	-
Over 6 months	6個月以上	57,036	61,010
		58,416	61,010

Notes to the Interim Condensed Consolidated Financial Statements 簡明綜合中期財務報表附註

13. TRADE AND OTHER PAYABLES (continued)

The average credit period on trade purchases granted by suppliers up to 90 days (31 December 2022: 90 days).

As at 30 June 2023 and 31 December 2022, included in the Group's accruals and other payables are an amount due to Titron Group Holdings Limited ("TGHL") of approximately HK\$1,700,000 and the cash consideration of HK\$7,500,000 payable to the Vendors of Titron Group (as defined and detailed in the Company's circular dated 12 August 2011) arising from the acquisition of Titron Group in 2011. TGHL was one of the Vendors of Titron Group. Titron Group is principally engaged in the Medical Products Business and the Plastic Products Business. One of the shareholders of TGHL, Mr. Yip Wai Lun, Alvin, was a former shareholder and the former Chairman and Managing Director of the Company. The amounts were unsecured, interest-free and repayable on demand as at 30 June 2023 and 31 December 2022.

13. 貿易及其他應付款項 (續)

供應商授予貿易採購之平均信貸期最多為90天(二零二二年十二月三十一日: 90天)。

於二零二三年六月三十日及二零二二年十二月三十一日, 本集團之應計款項及其他應付款項包括一筆應付Titron Group Holdings Limited (「TGHL」)之款項約1,700,000港元及於二零一一年收購德隆集團(定義及詳情見本公司日期為二零一一年八月十二日之通函)產生之應付德隆集團賣方之現金代價7,500,000港元。TGHL為德隆集團之其中一位賣方。德隆集團主要從事醫療產品業務及塑膠產品業務。TGHL之一名股東葉偉倫先生為本公司前股東及前主席兼董事總經理。於二零二三年六月三十日及二零二二年十二月三十一日, 該款項為無抵押、免息及須按要求償還。

14. SHARE CAPITAL

14. 股本

		Number of shares	Amount HK\$'000
		股份數目	金額 千港元
Authorised:	法定:		
Balance as at 31 December 2022 and 30 June 2023	於二零二二年十二月三十一日及二零二三年六月三十日之結餘	80,000,000,000	400,000
Issued and fully paid:	已發行及繳足:		
Balance as at 1 January 2023	於二零二三年一月一日之結餘	483,775,896	24,189
Rights issue (Note)	供股(附註)	483,775,896	24,189
Balance as at 30 June 2023	於二零二三年六月三十日之結餘	967,551,792	48,378

Note:

During the six months ended 30 June 2023, the Group carried out the rights issue on basis of one rights shares for every one Share. The Group completed the rights issue on 1 February 2023.

附註:

截至二零二三年六月三十日止六個月, 本集團按每持有一股股份獲發一股供股股份的基準進行供股。本集團已於二零二三年二月一日完成供股。

Notes to the Interim Condensed Consolidated Financial Statements

簡明綜合中期財務報表附註

15. RELATED PARTY TRANSACTIONS

Compensation of key management personnel

The remuneration of Directors and other member of key management during the period was as follows:

Salaries and short-term employee benefits	薪金及短期僱員福利
Post-employment benefits	離職後福利

15. 關連人士交易

主要管理人員之報酬

董事及其他主要管理層成員於期內之薪酬如下：

Six months ended 30 June	
截至六月三十日止六個月	
2023	2022
Unaudited	Unaudited
HK\$'000	HK\$'000
二零二三年	二零二二年
未經審核	未經審核
千港元	千港元
426	438
-	-
426	438

16. CAPITAL COMMITMENTS

The Group had no significant capital commitment as at 30 June 2023 and 31 December 2022.

17. EVENTS AFTER THE REPORTING PERIOD

There is no material events after the six months ended 30 June 2023 as at the date of this report.

16. 資本承擔

於二零二三年六月三十日及二零二二年十二月三十一日，本集團並無重大資本承擔。

17. 報告期後事項

於本報告日期，截至二零二三年六月三十日止六個月後並無任何重大事項。